



Supplemental Figures

Supplement 1

A



B



Supplement 2




Figure 1: anti-CRMP2-pTyr479 antibody characterization

A- Anti-CRMP2-pTyr479 antibody was raised against a peptide bearing phosphorylated Y479, p-Tyr479. Rabbit serum was negatively purified on Tyr479 peptide then positively purified on p-Tyr479 peptide. Elisa performed on each peptide showed serum specificity for p-Tyr479 peptide.

B- Treatment with phosphatase (Calf Intestinal Phosphatase, 120 units, 1h30, 30°C) reduced CRMP2-pTyr form while un-phosphorylated CRMP2 was still detected with CRMP2-pep4 antibody.

Figure 2: relationship between CRMP2-Thr509/514 and CRMP2-pTyr479

The T-cell line C91PL, which constitutively express CRMP2-p479 were treated with the cell permeable peptide GSK-3β inhibitor L803-mts. GSK-3β blockade reduced the CRMP2-Thr509/514 as expected. Consecutive increase in CRMP2-Tyr479 revealed a link between Tyr479 and Thr509/514 phosphorylation.